Press "Enter" to skip to content

New patent expiration for Gilead Sciences drug ATRIPLA

0
Copyright © DrugPatentWatch. Originally published at New patent expiration for Gilead Sciences drug ATRIPLA

Annual Drug Patent Expirations for ATRIPLA
Annual Drug Patent Expirations for ATRIPLA

Atripla is a drug marketed by Gilead Sciences and is included in one NDA. It is available from two suppliers. There are nine patents protecting this drug and one Paragraph IV challenge.

Drug patent litigation for ATRIPLA.

This drug has one hundred and fourteen patent family members in thirty-one countries.

The generic ingredient in ATRIPLA is efavirenz; emtricitabine; tenofovir disoproxil fumarate. Two suppliers are listed for this compound. Additional details are available on the efavirenz; emtricitabine; tenofovir disoproxil fumarate profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

Get the Daily Briefing or Try a trial

Copyright © DrugPatentWatch. Originally published at New patent expiration for Gilead Sciences drug ATRIPLA
Online Certificate Course

Decision-Making for Generic Drug Entry & Branded Drug Lifecycle Management

  • When will key drug patents expire?
  • How can I find, evaluate, and plan for generic market entry opportunities?
  • How can I find proprietary out-of-court settlements and deal terms?
DrugPatentWatch - Make Better Decisions